POST Online Media Lite Edition


Pfizer thinking about consumer healthcare business sale

Staff Writer |
Pfizer said it was considering the sale or spin-off of its consumer healthcare business, putting a lip balm operation worth as much as $14 billion up for grabs.

Article continues below

Pfizer’s consumer healthcare business, whose brands include painkiller Advil and lip balm Chapstick, had revenue of about $3.4 billion in 2016.

Industry experts said it could fetch around four times sales, implying a potential value of up $14 billion.

Pfizer, which saw its shares rise about 1 percent at $36.50 in premarket trading, said it would decide on the future of its consumer unit during 2018.

Reuters first reported last November that a divestment of the Pfizer consumer business was under consideration.

What to read next

Pfizer to create three business segments
Pfizer officially withdraws from AstraZeneca deal
Pfizer and Allergan to merge in $160 billion deal